Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07167225 · ClinicalTrials.gov registry record

Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)

A clinical trial of Cigarette Smoking-Related Carcinoma and E-Cig Use, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT07167225: Recruiting study of Cigarette Smoking-Related Carcinoma and E-Cig Use, sponsored by Roswell Park Cancer Institute.

NCT07167225 is a study of Cigarette Smoking-Related Carcinoma and E-Cig Use that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 150 participants, below the 460-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07167225, a study of Cigarette Smoking-Related Carcinoma and E-Cig Use, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and/or cannabis products in the blood and urine of young adult users as well as the cannabis and nicotine use behaviors of consumers.

Primary Outcome

Will compare the mean biomarker levels between groups using a one-way ANOVA model, with Bonferroni-adjusted pairwise comparisons, as appropriate.

Interventions

  • OTHER Effectiveness of different recruitment approaches
  • OTHER Choice of study completion locations
  • OTHER Cannabis Engagement Assessment
  • OTHER E-cigarette dependence Scale

Study Locations (1)

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-04-03
Est. Completion 2028-09-01
Roswell Park Cancer Institute

365 total trials

What NCT07167225 shows while recruiting

NCT07167225 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 460-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (67% lower).

The record links to 2 conditions, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Effectiveness of different recruitment approaches is the first listed.

NCT07167225 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07167225 about?

NCT07167225 is a clinical study titled "Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)". This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and/or cannabis products in the blood and urine of young adult users as well as the cannabis and nicotine use behaviors of consumers.

What is the current status of trial NCT07167225?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-04-03. Estimated completion is 2028-09-01.

What conditions does trial NCT07167225 study?

This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma, E-Cig Use.

What interventions are being tested in trial NCT07167225?

The interventions under investigation include: Effectiveness of different recruitment approaches (OTHER), Choice of study completion locations (OTHER), Cannabis Engagement Assessment (OTHER), E-cigarette dependence Scale (OTHER).

Who is sponsoring clinical trial NCT07167225?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07167225 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cigarette Smoking-Related Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07167225's enrollment target sits among peer trials

150 13th of 21 higher than 9 of 21 other Cigarette Smoking-Related Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cigarette Smoking-Related Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07167225, the US trial registry maintained by the National Library of Medicine. NCT07167225 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.